GRAM

GRAM Launches New Americas Buyout Fund to Invest in the Hispanic Ecosystem

Retrieved on: 
Wednesday, November 8, 2023

The agreement paves the way for GRAM’s newest private equity strategy to launch a standalone investment fund that will provide GRAM with access to the Carlyle network and global industry experts.

Key Points: 
  • The agreement paves the way for GRAM’s newest private equity strategy to launch a standalone investment fund that will provide GRAM with access to the Carlyle network and global industry experts.
  • GRAM’s new buyout fund, ABF, will target opportunities throughout the Hispanic ecosystem across the Americas, and is aiming to begin its fundraising process in Q1 2024.
  • As part of the agreement, Carlyle has the option to invest alongside GRAM in new deals going forward.
  • “The Hispanic markets in Latin America and the US present an excellent opportunity for investors, however navigating them requires a skilled team and the right relationships.

Iskra x Grampus CWC Launching Two New Web 3 Games Following Successful Global Launch of Norma in Metaland

Retrieved on: 
Thursday, October 26, 2023

SINGAPORE, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Following the successful global launch of Norma in Metaland, top-ranked Web 3 game platform, Iskra, has signed two new Web 3 games with Grampus CWC, a blockchain subsidiary of Grampus.

Key Points: 
  • SINGAPORE, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Following the successful global launch of Norma in Metaland, top-ranked Web 3 game platform, Iskra, has signed two new Web 3 games with Grampus CWC, a blockchain subsidiary of Grampus.
  • Norma In Metaland is a Web 3 reboot of the game 'Cooking Adventure', which has achieved 30 million downloads.
  • Since its July 31, 2023, launch, Norma in Metaland has marked noteworthy achievements.
  • Iskra anticipates further collaborations with Grampus CWC on upcoming game titles as part of its ongoing global expansion.

Gabbi Raises $4.4 Million to Bring Breast Cancer Early Detection Support Directly to Women

Retrieved on: 
Thursday, October 27, 2022

PORTLAND, Ore., Oct. 27, 2022 /PRNewswire/ -- Gabbi, the risk assessment and care navigation company, today announced it has raised a round of $4.4 million to help tackle its mission of ensuring breast cancer is detected at the earliest possible stages when it is a treatable, survivable disease. Bread and Butter Ventures led the round which also saw participation from Female Founders Fund, WR Hambrecht, Phoenix Rising, Claridge Ventures Advisors VC, Coyote Ventures, Gaingels and prominent angels including, David Kidder, Sarah Jones Simmer and Naseem Sayani also invested.

Key Points: 
  • "I know firsthand the difference of a timely diagnosiswhen caught early, the five-year survival rate is 99%!
  • Christine lost her mother to breast cancer a decade ago after a delayed diagnosis.
  • Gabbi is a revolutionary risk assessment and care navigation solution, delivering immediate, accurate results for women of all ages and all ethnicities.
  • Gabbi will launch at the beginning of 2023 via employers who will provide Gabbi as a benefit to their employees.

Bavarian Nordic Expands Capacity with U.S. Contract Manufacturer for Filling of Smallpox/Monkeypox Vaccines

Retrieved on: 
Thursday, August 18, 2022

By adding the capacity of GRAM to fulfil a significant part of the orders from BARDA, Bavarian Nordic will be able to expedite delivery of vials to the U.S. while also freeing up capacity for other countries.

Key Points: 
  • By adding the capacity of GRAM to fulfil a significant part of the orders from BARDA, Bavarian Nordic will be able to expedite delivery of vials to the U.S. while also freeing up capacity for other countries.
  • With this agreement we will significantly expand our manufacturing capabilities into the United States allowing Bavarian Nordic to meet the growing worldwide demand.
  • Under this contract Bavarian Nordic has produced bulk vaccine, corresponding to approximately 13 million doses.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.

Groundbreaking Data-Sharing Initiative Launches to Increase Understanding of Antimicrobial Resistance

Retrieved on: 
Tuesday, June 21, 2022

CAMBRIDGE, Mass., June 21, 2022 /PRNewswire/ -- The Antimicrobial Resistance Register, unveiled today by the nonprofit organization Vivli, makes it possible for biopharmaceutical companies to share susceptibility data on infection causing pathogens for the first time ever in one online platform, marking a critical step in combating the growing global health threat of antimicrobial resistance. With the active participation from leading pharmaceutical and biotech enterprises, researchers will be able to use the AMR Register to translate masses of antimicrobial resistance surveillance data into meaningful action that saves lives and preserves antibiotics for future generations.

Key Points: 
  • According to latest figures from the GRAM report, almost 5 million people died worldwide with an antimicrobial resistant infection.
  • If left unchecked, the scale of antimicrobial resistance will quickly outpace what we have experienced with COVID-19, with deaths rising to 10 million per year by 2050, according to the United Nations.
  • "Our understanding of how to control antimicrobial resistant infections and how best to protect human health hinges on better access to surveillance data.
  • Data sharing initiatives include the Antimicrobial Resistance Register for AMR surveillance data and the Vivli Platform for clinical trial data.

Riiid Expands its NLP Capabilities, Presenting Innovative AI Models at the World's Leading NLP Conferences

Retrieved on: 
Monday, May 16, 2022

SAN RAMON, Calif., May 16, 2022 /PRNewswire/ -- Riiid, a leading AI Education solutions company and a member of Born2global Centre, today announced two of its new AI research studies that will be presented at the upcoming Association for Computational Linguistics (ACL) and the North American Chapter of the Association for Computational Linguistics (NAACL), the world's leading Natural Language Processing (NLP) conferences. With this ground-breaking research, the company will continue to extend its AI capabilities with NLP technology to build extensive new educational content-aware AI models.

Key Points: 
  • With this ground-breaking research, the company will continue to extend its AI capabilities with NLP technology to build extensive new educational content-aware AI models.
  • "With this technology, Riiid can easily provide high-quality cross-domain KT models, which will open our doors to countless domains with small or no interaction data.
  • Riiid is a leading pioneer in AI solutions for education, named in the 2021 CB Insights AI 100 list of the most innovative AI startups.
  • As a leading force in AI technology, Riiid has published research papers at top AI conferences including NeurIPS and AAAI.

Grand River Aseptic Manufacturing Announces Addition of Chief Operating Officer as Growth Continues

Retrieved on: 
Wednesday, April 6, 2022

GRAND RAPIDS, Mich., April 6, 2022 /PRNewswire/ -- Grand River Aseptic Manufacturing ("GRAM"), a leading parenteral contract development and manufacturing organization (CDMO), recently announced that Bernie King has been appointed Chief Operating Officer, a new position within GRAM.

Key Points: 
  • GRAND RAPIDS, Mich., April 6, 2022 /PRNewswire/ -- Grand River Aseptic Manufacturing ("GRAM"), a leading parenteral contract development and manufacturing organization (CDMO), recently announced that Bernie King has been appointed Chief Operating Officer, a new position within GRAM.
  • "Bernie's executive level experience in operations, supply chain, and manufacturing make him a perfect fit as GRAM's Chief Operating Officer.
  • He brings in-depth expertise leading manufacturing and site operations, global supply chain management, and strategic planning to his new role at GRAM.
  • About Grand River Aseptic Manufacturing, Inc.
    Grand River Aseptic Manufacturing, Inc. ("GRAM"), a leading parenteral contract development and manufacturing organization, delivers customized solutions to meet clients' fill and finish needs from development through commercialization.

ArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial Resistance

Retrieved on: 
Thursday, March 3, 2022

ArrePath, an anti-infective drug discovery company addressing the global health challenge of drug resistant infections, announced today that it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome antimicrobial resistance (AMR).

Key Points: 
  • ArrePath, an anti-infective drug discovery company addressing the global health challenge of drug resistant infections, announced today that it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome antimicrobial resistance (AMR).
  • New classes of antibiotics that more effectively treat drug resistant infections and overcome antimicrobial resistance are urgently needed.
  • Antimicrobial resistance is an area with critical unmet medical need and is one of the Boehringer Ingelheim Venture Funds investment focuses globally.
  • This financing is a strong vote of confidence, by a global investment syndicate, in our platform and its enormous potential in anti-infective drug discovery.